The global glaucoma market size is expected to reach USD 9,154.4 million by 2032, according to a new study by Polaris Market Research. The report “Glaucoma Market Share, Size, Trends, Industry Analysis Report, By Drug Class; By Distribution Channel (Hospital pharmacy, Retail pharmacy, and Online pharmacy); By Disease Type; By Region; Segment Forecast, 2023 - 2032” gives a detailed insight into current market dynamics and provides analysis on future market growth.
Glaucoma, a prevalent ocular condition, is expected to affect many individuals worldwide. The World Glaucoma Association predicts the disease will impact 79.6 million people in 2020 and rise to 111.8 million by 2040. In the United States alone, glaucoma affects 3 million people, with 2.7 million of them being over 40. The increasing incidence rates and advancements in therapeutic strategies are driving the expansion of the glaucoma market.
Technological improvements in the ophthalmology sector play a significant role in the positive outlook for the glaucoma market. The demand for cutting-edge surgical techniques, such as micro-invasive glaucoma surgery (MIGS) and selective laser trabeculoplasty (SLT), is driving industry growth. Moreover, advancements in medical imaging, optical coherence tomography (OCT), and progression analysis software are increasing the popularity of optometrists. Incorporating laser therapies as first-line treatments and developing new medications for glaucoma also contribute to the market's expansion.
Do you have any questions? Would you like to request a sample or make an inquiry before purchasing this report? Simply click the link below: https://www.polarismarketresearch.com/industry-analysis/glaucoma-market/request-for-sample
The COVID-19 pandemic had adverse effects on the sales of glaucoma treatments. Preventive lockdown measures and diverted healthcare resources limited access to care for glaucoma patients. Many ophthalmology clinics were repurposed as COVID-19 wards, which hindered patient follow-ups. Furthermore, the fear of contracting the virus deterred older individuals from visiting clinical settings, decreasing market demand. However, telemedicine platforms emerged as a viable solution during the pandemic, enabling patients to access prompt care and contributing to the overall expansion of the industry.
Glaucoma Market Report Highlights
Polaris Market Research has segmented the Glaucoma market report based on drug class, distribution channel, disease type, and region:
Glaucoma, Drug Class Outlook (Revenue - USD Million, 2019 - 2032)
Glaucoma, Distribution Channel Outlook (Revenue - USD Million, 2019 - 2032)
Glaucoma, Disease Type Outlook (Revenue - USD Million, 2019 - 2032)
Glaucoma, Regional Outlook (Revenue - USD Million, 2019 - 2032)
Report Attributes |
Details |
Market size value in 2023 |
USD 6,905.0 million |
Revenue forecast in 2032 |
USD 9,154.4 million |
CAGR |
3.2% from 2023 – 2032 |
Base year |
2022 |
Historical data |
2019 – 2021 |
Forecast period |
2023 – 2032 |
Quantitative units |
Revenue in USD million and CAGR from 2023 to 2032 |
Segments Covered |
By Drug Class, By Distribution Channel, By Disease Type, By Region |
Regional scope |
North America, Europe, Asia Pacific, Latin America, Middle East & Africa |
Key Companies |
Allergan PLC, Aristo Pharmaceuticals Pvt. Ltd., Aerie Pharmaceuticals Company, Akorn operating company LLC, Bausch & Lomb Incorporated, Cipla Incorporation, Fera Pharmaceuticals, LLC, Inotek Pharmaceuticals, Merck KGaA, Novartis AG, Pfizer Incorporation, Santen Pharmaceutical Co., Ltd., Teva Pharmaceutical Industries Ltd., and Valeant Pharmaceuticals International, Inc. |
For Specific Research Requirements |